Advertisement

PharmacoEconomics & Outcomes News

, Volume 840, Issue 1, pp 20–20 | Cite as

Osimertinib cost effective in advanced NSCLC in China

Clinical study
  • 4 Downloads

Reference

  1. Guan H, et al. Cost-Effectiveness of Osimertinib as a Second-Line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China. Clinical Therapeutics : 10 Oct 2019. Available from: URL: http://doi.org/10.1016/j.clinthera.2019.09.008

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations